“We want to work with great partners with complementary skills and resources."

- Sylvie Ryckebusch, Chief Business Officer at BioInvent.

Contact

All of our partnerships are important.

Our academic partnerships enable us to bring world-class scientific expertise to our programs.

As our clinical programs advance, partnerships with commercial-stage pharmaceutical companies are important to ensure that our drugs have the best chance to reach the market and benefit patients.

What kinds of partnerships do we want to establish?

  • Scientific collaborations with world-class experts
  • Target and antibody discovery collaborations based on F.I.R.S.T™ and n-CoDeR to help partners build a pipeline of novel assets
  • Development and commercial partnerships for our clinical-stage assets.

Active partnerships:


casi
  • Exclusive licensing agreement with CASI Pharmaceuticals for BI-1206 in mainland China, Taiwan, Hong Kong and Macau.
transgene-logotype
  • Co-development collaboration (50/50 split of costs and profits) combining Transgene's oncolytic virus platform with BioInvent's proprietary antibodies.
smd
  • Five clinical trial collaboration and supply agreements with MSD (known as Merck & Co.,Inc., Rahway, NJ, USA in the United States and Canada), to evaluate BI-1808, BI-1910, BI-1206, BI-1607 and BT-001 in combination with Keytruda®. A supply agreement with AstraZeneca for the supply of Calquence® to the BI-1206 program in NHL.
Antibody discovery partnerships
  • Antibody discovery partnerships
 Research collaborations
  •  Research collaborations

FIVE CLINICAL PROJECTS OUTLICENSED

BioInvent currently has five clinical projects outlicensed to other companies. Long-term, these projects hold real financial potential. In the short term, say five years, BioInvent may receive minor clinical milestone payments, but the real upside in these projects lies in commercial milestones and potential royalties five to ten years from now. It is impossible to know if any of BioInvent’s external projects will go all the way to market but statistically it is highly probable that at least one or two will be successful.